Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Ipilimumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms IDEATE
- Sponsors Bristol-Myers Squibb
- 03 Aug 2017 This trial has been completed in Germany (End Date:14-12-2016)
- 14 May 2017 This trial has been completed in Denmark as per European Clinical Trials Database record.
- 26 Feb 2017 This trial was completed in Austria, according to European Clinical Trials Database.